Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis ...

Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Extends Pediatric Psoriasis Study: What ...

Over 8 million adults in the U.S. experience plaque psoriasis — a chronic autoimmune disease that causes painful, raised, scaly spots on the skin. People with plaque psoriasis often employ a host of ...

Early Thursday, Takeda revealed top-line data for two pivotal phase 3 trials of its next-gen, highly selective oral tyrosine ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...

Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

Belgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA ...

Emirates Drug Establishment Approves Tapinarof Cream 1%, A New Treatment For Plaque Psoriasis In Adults And Atopic Dermatitis ...